Bill > SB29

This bill requires licensed healthcare practitioners to offer pharmacogenomic testing to patients before prescribing psychotropic drugs (medications that affect mental health and brain function). Specifically, the practitioner must inform the patient about the efficacy of pharmacogenomic testing, disclose whether the test is FDA-approved, and obtain the patient's informed consent before ordering the test. If the practitioner knows the test's cost, they must provide an estimate to the patient. If the patient agrees to the test, the practitioner must order and administer the pharmacogenomic test before prescribing any psychotropic medication. Pharmacogenomic testing is a type of genetic test that helps determine how an individual's genetic makeup might influence their response to certain medications, potentially improving treatment effectiveness and reducing adverse reactions. The bill will become effective on November 1, 2025, and will be codified in the Oklahoma Statutes as Section 7201 of Title 63.

Health and Social Services

http://www.oklegislature.gov/BillInfo.aspx?Bill=sb29&Session=2600